Printer Friendly

Gum Tech Announces Prominent Medical Journal to Publish Study on Revolutionary Cold Remedy; Zicam Reduced Duration of Common Cold by an Average of 85%.

WOODLAND HILLS, Calif.--(BUSINESS WIRE)--November 1, 1999--

Gel Tech LLC, a joint venture between GumTech International, Inc., (Nasdaq:GUMM) and BioDelivery Technologies, Inc. today announced that the professional peer-reviewed American Journal of Infection Control (AJIC) will publish the results of a scientific study on Zicam(TM), a revolutionary over-the-counter homeopathic cold remedy. According to the initial study, a proprietary nasal solution, currently marketed by Gel Tech as Zicam(TM), reduced the duration of the common cold by an average of 85% and significantly reduced the severity of colds including nasal congestion, sneezing, coughing, and sore throat.

"We are very pleased that the significance of our initial research has been recognized with publication in AJIC. As the premier publication of infection control professionals, AJIC reaches physicians, nurses, epidemiologists and other health care professionals throughout the world. Publication in AJIC represents an important step in getting Zicam(TM) recognized and accepted by the medical profession as an important weapon in fighting that most common of all plagues -- the common cold," said R. Steven Davidson, Gel Tech's Chief Executive Officer.

AJIC, first published in 1973, is the official scientific publication of the American Association of Professionals in Infection Control and Epidemiology (APIC). In addition to peer-reviewed articles and original research across the field of infection control and epidemiology, including occupational health and disease prevention, AJIC publishes the official guidelines for infection control practices produced by APIC and the CDC (the Centers for Disease Control and Prevention).

"This initial research on Zicam is quite significant. The term `cure' is not scientifically applicable since the common cold is a self-limiting condition, but the degree of efficacy of the medication demonstrated by this first study is very impressive," said Dr. Michael Seidman, MD, FACS, a medical consultant to the company from the Department of Otolaryngology at Henry Ford Medical Center.

The Common Cold

The common cold is generally caused by an estimated two hundred viruses known as rhinoviruses (rhino means nose). These viruses, which primarily infect the upper respiratory tract, may enter the body through the nose, mouth or eyes, with the infection cycle beginning in the nasal cavity. Inside the nasal cavity, the virus infects the body by binding to ICAM-1 (Intercellular adhesion molecule-1) receptor sites located on the cells that line the nasal passageway. The virus enters those cells through the ICAM-1 binding site, and then uses the cells' own genetic material to replicate and infect the body. As the virus infects more and more nasal cells, the body's immune system is overwhelmed, leading to a full-blown cold.

Aside from the personal misery caused by the common cold during the average 10 - 14 day infection cycle, colds have a significant economic impact on society. Of the estimated one billion common colds that occur each year in the United States alone, more than 110 million are disabling, causing approximately 58 million bed days, 300 million days of restricted activity, 60 million lost days of school, and 50 million lost days of work. According to some estimates, colds are responsible for 30% of all missed school days and 40% of all lost work time, annually. $5.5 billion is spent on colds (not including prescription medicines) each year in the United States with about $2.3 billion spent on over-the-counter cold remedies.

The Study

"This initial clinical research showed that participants who used Zicam(TM) at the onset of symptoms significantly reduced the duration of their colds," said Dr. Charles B. Hensley, chief of research at Gel Tech, LLC. The double blind placebo-controlled study was conducted by scientists from Gel Tech over a two-cold season period. A total of 104 subjects presenting with at least 3 of 9 cold symptoms for a period of 24 hours or less participated in the study. Patients received a dosage of either the proprietary nasal gel containing the active ingredient or a placebo 4 times daily. Colds were determined to be over when all symptoms were resolved. Subjects receiving the active ingredient found in Zicam(TM) had colds which lasted only 1.5 days on average, while subjects receiving the placebo had colds which lasted 9.8 days on average.


"Unlike most other OTC and prescription cold remedies, which typically were designed only to suppress or mask cold symptoms, Zicam(TM) was designed to treat the duration and severity of the cold," said Dr. Hensley. Research suggests that ionic zinc fills the grooves or canyons on the rhinovirus thus inhibiting or blocking the virus's ability to bind with the ICAM-1 receptor sites on the cells lining the nasal cavity, preventing or interrupting the infection cycle.

Zicam uses a patent-pending gel matrix to apply a proprietary emulsification of ionic zinc, known as Zinullose(TM), directly to the nasal cavity. According to Hensley, "This revolutionary method of applying ionic zinc was designed to have two principle advantages. First, it was designed to apply the ionic zinc directly to the site of infection, the nasal cavity. Second, it was designed to suspend the ionic zinc long enough to allow it to block the virus. As an added benefit, the gel keeps the nasal passages moist and protected." Hensley added that Gel Tech was planning future research into the ability of Zinullose(TM) to block the rhinovirus from binding with the ICAM-1 receptor sites.

Zicam(TM) is developed by Gel Tech, LLC, a joint venture between GumTech International, Inc., (Nasdaq:GUMM) a publicly held company located in Phoenix, AZ and BioDelivery Technologies, Inc., a privately held biotechnology company. Gum Tech and BDT are devoted to the development of unique systems for delivering bioactive compounds.

Zicam(TM) is currently available at Drug Stores, Grocery Stores, Pharmacies, Mass Merchants, Club Stores and Convenience Stores nationwide. For more information, call 1-877-ZICAM-COLD or log onto

Gum Tech Forward-Looking Statement:

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's anticipated growth in business and future results of operations. These forward-looking statements are based on the company's expectations and are subject to a number of risks and uncertainties, many of which cannot be predicted or quantified and are beyond the company's control. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the company's expectations include unfavorable results from pending clinical trials regarding the efficacy of ZICAM(TM), lack of market acceptance for or uncertainties concerning the efficacy of ZICAM, a decrease in the level of reorders from existing customers, financial difficulties encountered by one or more of the company's principal customers, difficulties in obtaining additional capital for marketing, research and development, and other expenses, the possibility of material charges incurred as a result of prior activities, aggressive pricing and marketing efforts by competitors, unavailability of third-party material products at reasonable prices, inventory obsolescence due to shifts in market demand, and material litigation involving product liabilities and consumers issues. Other factors that could cause actual results to differ materially from the company's expectations are described in the company's reports filed pursuant to the Securities Exchange Act of 1934.

SOURCE: Gum Tech International
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 1, 1999
Previous Article:Enigma Completes Acquisition of Inso Corporation's Technical Publishing Business; DynaWeb/Text and Synex Now Included in Enigma's Comprehensive...
Next Article:Iconomy Shapes E-Commerce Solutions Marketspace; Industry Leader Characterizes Market with Rollout of Three Lines of Business.

Related Articles
The Cold War.
Zinc nasal gel for the treatment of common cold symptoms: A double-blind, placebo-controlled trial.
In from the cold: do supplements work? (Cover Story).
Run away from cold and flu season.
Lawsuits sniff out zinc hazard in nasal cold remedy.
The cold war.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters